Prof. Joshua Guetzkow uncovers CDC’s OWN incriminating DATA, via VAERS,” Professor Joshua Guetzkow brings attention to several concerning safety signals found in the CDC’s COVID-19 vaccine data obtained through the Vaccine Adverse Events Reporting System (VAERS). The video sheds light on adverse events that have been largely disregarded by the CDC and FDA, including inflammation-related issues like myocarditis and pericarditis, as well as other serious adverse reactions. This article will delve deeper into the key points raised in the video and explore the implications of the CDC’s handling of vaccine data.
Table of contents
- Introduction
- The significance of safety signals
- Adverse events reported through VAERS
- Focus on cardiovascular and neurological adverse events
- Adverse events in the 12 to 17 age group
- Inflammation as a side effect of the COVID-19 vaccine
- Failure to consider the well-being of teenagers
- Misinterpretation of safety signals
- Underreporting of adverse events in Israel
- Conclusion
- FAQs
- Related Articles
Introduction
Professor Joshua Guetzkow reveals his findings after conducting a thorough examination of the CDC’s COVID-19 vaccine data obtained through the VAERS system. The analysis uncovers several safety signals that have been overlooked or downplayed by the CDC and FDA.
The significance of safety signals
Safety signals are crucial indicators of potential adverse reactions to vaccines. They help identify any risks associated with vaccination and allow for timely intervention to ensure public safety. Professor Guetzkow emphasizes the importance of thoroughly investigating safety signals to protect the well-being of vaccine recipients.
Adverse events reported through VAERS
The VAERS system has revealed a significant number of adverse events associated with COVID-19 vaccination. These events range from blood clotting and stroke to Bell’s palsy, genital ulcerations, and immune thrombocytopenia. Of particular concern is the higher reporting rate of adverse events in the 12 to 17 age group, indicating a need for closer scrutiny and consideration of the younger demographic’s well-being.
Focus on cardiovascular and neurological adverse events
Professor Guetzkow highlights the prevalence of adverse events related to the cardiovascular and neurological systems. Reports have shown chest pain, palpitations, atrial fibrillations, cardiac failure, tinnitus (associated with increased suicide risk), Bell’s palsy, dementia, and paresthesia. These adverse events raise concerns about the safety of the COVID-19 vaccine and warrant further investigation.
Adverse events in the 12 to 17 age group
The data obtained through a Freedom of Information Act (FOIA) request reveals a higher incidence of adverse events in the 12 to 17 age group. Despite these concerning findings, the CDC and FDA have largely disregarded the signals, leaving questions about their approach to ensuring the safety of younger vaccine recipients.
Inflammation as a side effect of the COVID-19 vaccine
Inflammation, particularly myocarditis and pericarditis, has emerged as a side effect of the COVID-19 vaccine. Professor Guetzkow explains how inflammation can be both beneficial and harmful but emphasizes that unnecessary inflammation caused by the vaccine raises concerns. The impact on younger age groups, such as 5 to 11-year-olds, is particularly alarming.
Failure to consider the well-being of teenagers
The CDC’s response to the pandemic has been criticized for its failure to adequately consider the well-being of teenagers. Despite a high percentage of teenagers being hospitalized after receiving the COVID-19 vaccine, the committee responsible for vaccine safety only focused on myocarditis and neglected other serious symptoms. This raises questions about the CDC’s approach to ensuring the safety of this vulnerable population.
Misinterpretation of safety signals
The CDC defines safety signals for new vaccines by comparing them to established vaccines. However, symptoms that were not previously reported for other vaccines are not considered safety signals. This approach disregards potential adverse reactions unique to the COVID-19 vaccine and undermines the comprehensive evaluation of its safety.
Underreporting of adverse events in Israel
In Israel, adverse events related to COVID-19 vaccination were heavily underreported due to discouragement or unwillingness among doctors to report events. Despite this, safety signals similar to those found in the CDC’s data were observed. The underreporting raises concerns about the transparency and reliability of adverse event reporting systems.
Conclusion
Professor Joshua Guetzkow sheds light on critical safety signals identified in the CDC’s COVID-19 vaccine data obtained through VAERS. It highlights the need for a comprehensive evaluation of adverse events and a closer consideration of the well-being of different age groups, particularly teenagers. The CDC and FDA’s response to these safety signals raise questions about their commitment to public safety and transparency.
FAQs
The VAERS system is an essential monitoring system for vaccines. While it allows for the detection of safety signals, it is important to note that the reported events may not always be directly caused by vaccines. Further investigations and analysis are required to establish causality and determine the true safety profile of vaccines.
Adverse events reported through VAERS vary in nature and severity. Some of the commonly reported adverse events include fever, injection site reactions, fatigue, headache, muscle pain, and allergic reactions. However, it is crucial to remember that the frequency of reported adverse events does not necessarily reflect the true incidence or causality.
Cardiovascular and neurological adverse events are of concern because they involve vital systems in the body. Events such as chest pain, palpitations, atrial fibrillations, cardiac failure, tinnitus, Bell’s palsy, dementia, and paresthesia can have significant implications for an individual’s health and well-being. Thorough evaluation and monitoring of these events are necessary to understand their association with COVID-19 vaccines and mitigate potential risks.
The CDC’s response to adverse events in the 12 to 17 age group has been a subject of concern. Despite a higher reporting rate of adverse events in this age group, the CDC’s focus has primarily been on myocarditis, while other serious symptoms have been overlooked. This approach raises questions about whether the well-being of teenagers has been adequately considered in the pandemic response.
To enhance vaccine safety monitoring and reporting, it is crucial to promote transparency, encourage healthcare professionals to report adverse events, and educate the public about the importance of reporting. Continuous evaluation of safety signals, conducting robust studies, and maintaining open channels of communication between regulatory authorities, healthcare providers, and the public are key to improving vaccine safety monitoring and reporting systems.
In conclusion, Professor Joshua Guetzkow’s analysis of the CDC’s COVID-19 vaccine data through VAERS reveals significant safety signals that raise concerns about the vaccine’s potential adverse reactions. It is crucial for regulatory authorities to thoroughly investigate and address these signals to ensure the safety and well-being of the population. The video summary emphasizes the need for transparency, thorough evaluation, and a comprehensive approach to vaccine safety.
Related Articles
Discover more from Randy Bock MD PC
Subscribe to get the latest posts sent to your email.
